Treatment of moderate to severe Crohn’s disease (CD) typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and progresses to more-potent drugs, such as immunosuppressants and/or biologics. The TNF-α inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe CD. However, these agents have safety risks and efficacy limitations. Two additional biological agents with novel mechanisms of action (i.e., Takeda’s Entyvio, a CAM inhibitor approved in 2014, and Janssen’s Stelara, an IL-12/23 inhibitor approved in 2016) have expanded the treatment options for moderate to severe CD; however, significant need remains, especially for patients refractory to currently available therapies.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European gastroenterologists fielded in January2019.
Key companies: AbbVie, Galapagos NV, Gilead, Janssen, Merck & Co., Takeda, TiGenix, Boehringer Ingelheim, Allergan, Celgene, Roche
Key drugs: Humira, Remicade, Entyvio, Stelara, Cimzia, infliximab biosimilars, adalimumab biosimilars